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ABSTRACT The RNase A mismatch cleavage method has
been applied to the characterization ofnatural genetic variation
of human immunodeficiency virus (HIV) from different geo-
graphical areas. The approach provides a rapid and simple
assay for the analysis of differences in closely related viral
isolates and allows the establishment of phylogenetic relation-
ships between epidemiologically distinct viruses. Our results
show a broad clustering ofcirculating viruses according to their
geographical distribution. We also have analyzed the temporal
appearance of mutations associated with the acquisition of
resistance to 3'-azido-3'-deoxythymidine (AZT). The results
show that mutations in codon 215 of the viral reverse tran-
scriptase can be detected readily by this method in HIV isolates
and also directly in peripheral blood from HIV-infected indi-
viduals after in vitro amplification of viral sequences with the
polymerase chain reaction. The specific recurrence of identical
double-nucleotide substitutions in epidemiologically and geo-
graphically distant viruses suggests that the restricted amino
acid substitutions at this position selected by drug exposure are
a critical, rate-limiting step in the acqulisition of drug resis-
tance.
Human immunodeficiency virus (HIV) is a retrovirus of the
lentivirus family, which is responsible for AIDS and other
related diseases (1, 2). The great genetic variability of HIV
(3), a common property ofRNA viruses (4, 5), which reflects
the quasi-species distribution of the viral populations (6), has
profound implications in its biology and pathogenicity (7).
Marked variations in antigenic reactivity and nucleotide
sequence have been also documented in isolates from differ-
ent individuals (8). The availability of simple assays to
discriminate and characterize viral isolates could help to
address many unanswered questions regarding the biology
and epidemiology of the virus, such as the appearance ofnew
phenotypic variants, their geographical distribution, and the
role of immunity in the selection of variants (9).
Although presently there is no cure for the disease, 3'-
azido-3'-deoxythymidine (AZT; also called zidovudine) has
prolonged survival and reduced morbidity in patients in
several stages of HIV infection (10). Unfortunately, consis-
tent with the intrinsic high mutation rate ofRNA viruses (11),
resistance to the drug appeared after prolonged therapy (12).
The AZT-resistant phenotype is attributable to four amino
acid substitutions in the viral reverse transcriptase (RT),
which are the result of single nucleotide changes in codons
67, 70, and 219 and of two adjacent base substitutions in
codon 215 (13).
The ability ofRNase A to recognize and cleave single-base
mismatches in RNA-RNA and RNA-DNA hybrids can be
exploited for the detection of point mutations (14, 15) and for
the analysis ofgenetic variability ofRNA viruses (16, 17). We
have used this approach for the characterization of genetic
variation of HIV isolates of different epidemiological origin
and geographical distribution and for the detection of viruses
resistant to AZT.
MATERIALS AND METHODS
Origin and Isolation of Viral Strains. The viruses used in
this study (Table 1) were from patients with AIDS or AIDS-
related complex (ARC), mainly homosexuals in San Diego,
CA, or intravenous (i.v.) drug abusers and infected children
of i.v. drug abusers in Madrid, Spain. A set of viruses from
five individuals on AZT therapy (samples 12, 18, 22, 26, and
36) has been described (12, 13) and includes samples obtained
at the beginning of the treatment (i.e., 12/1) and subsequent
isolates (i.e., 12/2). HIV isolates originally called human
T-cell lymphotropic virus type III-namely, HTLV-IIIB (ref.
18; henceforth referred to as IIIB) and HTLV-IIIRF (ref. 19;
henceforth referred to as RF)-and HIV isolate SF-2 (ref. 20;
originally called ARV-2) were used as reference strains.
Viruses were isolated by cocultivation of peripheral blood
lymphocytes (PBL) from infected individuals with PBL from
healthy donors. When positive for p24 antigen (Abbott),
cultures were grown in H9 or MT-2 human T cells for one or
two passages as described (21). For the AZT studies, viruses
recovered by transfecting MT-2 cells with clones HXB2-D (a
clone of IIIB isolate) and pHIVRTMC were used as negative
and positive controls, respectively. pHIVRTMC, a gift from
B. Larder, is the HXB2-D clone with the four mutations at
codons 67, 70, 215, and 219 in the RT gene that confer the
resistant phenotype to AZT introduced by in vitro mutagen-
esis (13).
Plasmids. Plasmid pBH10-R3 (gift of R. Gallo) is an almost
full-length clone of the HIV IIIB isolate genome (18) cloned
into the Sst I site of pSP64 (Promega). Plasmid pEH was
constructed by deleting the 4.2-kilobase (kb) 5'-end EcoRI
fragment ofpBH10-R3 by partial digestion with this enzyme.
Subsequently, the 1.5-kb 3'-end HindIII fragment was also
deleted. pPSP is the 1.2-kb Pvu II-Spe I fragment of pP-l (at
positions 2878 and in the polylinker, respectively) cloned into
the pBluescript SK(-) vector (Stratagene). pP-1 is the 2.5-kb
Abbreviations: ARC, AIDS-related complex; HIV, human immuno-
deficiency virus; AZT, 3'-azido-3'-deoxythymidine; RT, reverse
transcriptase; HTLV-III, HIV isolates called human T-cell lympho-
tropic virus type III; PBL, peripheral blood lymphocytes; PCR,
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Table 1. Detection of AZT-resistance mutations in HIV by the
RNase A mismatch method
Case Months* Sensitivityt RNasef Sequence§
San Diego, CA
12/2 1 0.01 - WT
12/4 25 2.0 + MUT
18/1 0 0.01 - WT
18/3 16 4.0 + MUT
22/1 0 0.03 - WT
22/3 15 5.6 + MUT
26/1 0 0.01 - WT
26/2 11 2.8 + MUT
36/2 2 0.01 - WT
36/4 17 0.67 (+) MUT
36/5 25 5.6 (+) MUT
21-A 0 ND - ND
24-A 0 ND - ND
2-B/1 0 0.01 (+) WT
2-B/2 4 0.05 + WT/MUT
4-B 4 0.01 - WT
5-B 16 0.06 + MUT
7-B/1 0 0.01 - WT
7-B/2 16 0.18 (+) MUT
8-B 12 0.14 (+) WT
9-B 13 0.09 + MUT
10-B 14 0.09 (+) ND
11-B 12 0.17 + MUT
Madrid, Spain
58 0 ND - ND
59 0 ND - ND
61 0 ND - ND
75 0 ND - ND
80 0 ND - ND
106 0 ND - ND
108 11 ND + MUT
923 0 ND - ND
1067 14 ND + MUT
1578/1 0 ND - ND
1578/2 0 ND - ND
1862 <6 ND - WT
HIV isolates were from San Diego or Madrid patients, all of which
were males except 59, 61, 75, 106, 108, and 1578. Samples 1578/1 and
1578/2 were taken 13 months apart.
*Months on continued AZT therapy.
tValues indicate concentration ofAZT (AM) for 50%o inhibition in the
in vitro sensitivity assay (12). IC50 values of <0.05 are considered
sensitive (wild type) in phenotype.
tPresence (+) or absence (-) of the 214-nucleotide (nt) and 109-nt
bands diagnostic of mutation in codon 215 in the RT gene; "(+)"
indicates an incomplete pattern (one or more bands were missing;
see text).
§Sequence of codon 215 determined after amplification by the
polymerase chain reaction (PCR): Wild type (WT), ACC (Thr);
mutant (MUT), TTC (Phe, isolates 12, 22, and 108) or TAC (Tyr,
isolates 18, 26, and 36). Isolate 1067 was a mixture of both
mutations. ND, not determined.
Bgl II-EcoRI fragment ofpBH10-R3 (at positions 1640-4228)
that spans most of the polymerase (poo) gene, cloned into the
pBluescript SK(-) vector. The 520-nt ENV riboprobe was
synthesized with the phage SP6 RNA polymerase after
linearizing pEH with BgI II. The 323-nt RT 3' riboprobe was
generated with the phage T7 RNA polymerase after linear-
izing pPSP with EcoRV.
Hybridizations and RNase Digestions. Uniformly labeled
RNA probes were synthesized as described (16) by using
[32PJCTP (Amersham); 5 x 105 to 106 cpm of probe was
hybridized to -1 ,ug of total cellular RNA for 4 hr at 550C.
Total RNA was obtained from in vitro infected H9 or MT-2
cells or PBL as described (14). Hybrids were digested with
bovine pancreatic RNase A (40 Ag/ml; Pharmacia) at 30'C for
30 min. For the experiments with PCR-amplified DNA, the
RNA probe was synthesized in the presence of 200 AM CTP;
105 cpm of probe was hybridized to 1 pl of the PCR product
at 450C for 7 hr. Digestions were at 30'C for 15 min. The
RNase A resistant fragments were analyzed by denaturing
polyacrylamide gels as described (16).
PCR. Amplification with a thermostable thermos aquati-
cus (Taq) DNA polymerase (Cetus) was performed as de-
scribed (22) in a Perkin-Elmer Thermocycler with a profile of
a denaturing step at 940C for 35 sec, an annealing step for 1
min at 50'C, and an elongation step for 1 min at 720C. PCR
primers (Genetic Designs, Houston) 1U (5'-GGGATTA-
GATATCAGTACAATGTGCTT-3') and iD (5'-CGCTC-
GAGTTCATAACCCATCCAAAGG-3') correspond to posi-
tions 2550-2577 and 2810-2836 of HIV clone BH10 (18),
respectively. Nested primers 2U (5'-GGATCACCAG-
CAATATTCCAAAGT-3') and 2D (5'-GCGCTCGAGGT-
TCTTTCTGAT-3') correspond to positions 2592-2616 and
2791-2811, respectively. To analyze HIV sequences directly
from PBL, an initial reverse transcription reaction was per-
formed as described (23) by using total RNA and a primer
(5'-TCAGTCCAGCTGTCTTTTTCTGGC-3') correspond-
ing to positions 2867-2890. Ten microliters of the reverse
transcription reaction was used for a first round ofPCR with
primers 1U and iD for 25 cycles. One microliter of the
reaction was used in a second PCR with primers 2U and 2D
for 33 cycles.
RESULTS
Molecular Epidemiology of HIV. The RNase A mismatch
cleavage method is based on the ability of RNase A to
recognize and cleave single-base mismatches in RNA-RNA
or RNADNA hybrids. The marked sequence differences in
the genome of RNA viruses generate heterohybrids with
many mismatches, which after RNase treatment generate
electrophoretic band patterns that are characteristic finger-
prints for each strain. Comparative analysis of different viral
isolates can readily reveal genetic variations between closely
related viruses. At the same time, it can provide an estimation
of the degree of relatedness between different isolates by the
presence, number, and relative size of common bands be-
cause they represent similar, if not identical, nucleotide
sequence differences relative to the strain used as probe.
To study the natural variation ofHIV, we analyzed viruses
isolated from the same and different patients and from
different geographical locations. The riboprobes used in this
study are shown in Fig. 1 Top. The ENV probe spans the
RNA encoding the N-terminal region of the gp40 protein and
a small fragment of the C terminus of the gpl20 product. This
region shows a 6-7% variation between reference strains
(24). Two other more conserved regions are covered by the
RT and GAG probes with 3-4% interstrain variation (24). The
results for the ENV and RT 3' riboprobes are shown in Fig.
1. These experiments show the high degree of genetic het-
erogeneity of HIV as reflected by the distinct patterns of
protected bands obtained for the different isolates. Temporal
genetic variability within the same patients (1578 and 7-B),
was also apparent, in both env and the RT gene.
Despite this marked diversity, similarities in the env gene
were also evidenced among different isolates by the presence
of subsets of common bands. For instance, Spanish isolates
61, 1578, and 1910 or Californian isolates 11-B, 9-B, 5-B, and
7-B/2 shared two or more bands, but no common band was
present between these Spanish and Californian viruses.
Many isolates from San Diego also appeared to be related to
the Californian reference strain SF-2 as evidenced by the
presence of common bands marked by asterisks at the right.
Some of these viruses exhibited more than three common
bands (11-B, 8-B, 5-B, 7-B/2, and 26/1), and others exhibited
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ENV RT was similarly analyzed (Fig. 1 Bottom), several common
GP-12q GP-40 bands were also observed in various isolates (for instance,
B GH-4_ .3' isolates 36/1, 9-B, and 7-B/1). Analysis of the clinical data
ENV revealed a possible origin for other common bands, indicated
by arrows at the right. All viruses yielding at least two of
these bands (108, 1607, 2-B, 9-B, 11-B, and 5-B), with the
exception of2-B, were isolated from patients on AZT therapy
r (see Table 1). These bands could be due to the mutation(s)
__ r responsible for the acquisition of the resistant phenotype to
the drug (13). Two of the four described mutated positions
*'~ (codons 215 and 219) were covered by the RT 3' probe.
The origin of these bands was confirmed in another exper-
iment (Fig. 2). While the wild-type HXB2-D virus generated
Be~" the expected 323-nt protected RNA band (Fig. 2 Upper),
clone HIVRTMC to which the mutations responsible for the
resistance to AZT were introduced by in vitro mutagenesis
(13) generated a more complex pattern ofbands, including the
214-, 109-, and 100-nt bands diagnostic of mutations at
- codons 215 and 219 (Fig. 2 Lower). Other bands also present
are due to the existence of nucleotide changes in the clone















FIG. 1. RNase A mismatch cleavage analysis of RNA-RNA
heteroduplexes between different HIV isolates and antisense ribo-
probes of the IIIB reference strain. (Top) Map of the HIV genome
and the riboprobes used (GAG; RT 5'; RT 3'; and ENV). The
restriction endonucleases delimiting the riboprobes are: H, HindIII;
B, Bgl II; Ba, Bal I; R5, EcoRV; and P, Pvu II. The solid arrows
indicate the riboprobes for which experiments are shown below.
(Middle and Bottom) Total cellular RNA was obtained from cultured
cells infected with the virus isolates indicated vertically between the
gels. The RNA hybrids were digested with RNase A, and the
resistant fragments were electrophoresed in urea/polyacrylamide
gels. The gels were exposed to x-ray films for 1-3 days at -700C.
Lanes: M, 4X174 digested with Hae III to give molecular weight
markers; PBL, total RNA of uninfected control PBL; 61 through
1067, seven isolates from Madrid; 2-B through 26/1, 16 isolates from
San Diego; SF-2, RF, and lIIB, reference isolates; P. undigested
probes (400 cpm). The numbers indicate the position and size in
nucleotides of the fragments. Asterisks at the right of Middle
highlight the bands that are characteristic ofthe viruses related to the
SF-2 reference strain. Arrowheads at the right ofBottom indicate the
bands diagnostic of resistance to AZT.
at least two (36/1, 10-B, 9-B, 4-B, and 7-B/1) common bands.
Another group of viruses (2-B, 18/1, 21/1, and 22/1) yielded
fewer and larger bands, suggesting a closer relation to the
IIIB/LAV reference isolate of HIV. The absence of bands
characteristic of the SF-2 reference strain was shared by the
Spanish isolates with the exception of virus 61.
Detection of HIV Mutants Resistant to AZT. When the



















FIG. 2. Identification of AZT-resistant HIV genotypes by the
RNase A mismatch method. (Upper) Empty lines represent the
polymerase gene region. Solid vertical bars signal the localization of
the mutations responsible for the AZT-resistant phenotype, with the
italic numbers indicating the corresponding amino acids in the RT.
The region from Pvu 11 (P) to EcoRV (R5) coinciding with the RT 3'
probe used in the gel displayed in Lower is shown with the sizes in
nucleotides of the expected RNase A-protected RNA fragments of
wild-type (AZT sensitive) and mutant (AZT resistant) viruses, re-
spectively. (Lower) Lanes: M and P are as in Fig. 1; H9, total RNA
from uninfected H9 cells; HXB2-D and HIVRTMC, RNAs from
cultured cells infected with these clones, which were used as controls
for wild-type and mutant viruses, respectively; 22/1 through 21-A,
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degradation of the RNA, and/or the quasi-species nature of
the viral populations.
Two pairs of isolates (22 and 18) obtained either before (Fig.
2 Lower, lanes U) or after (lanes T) prolonged AZT treatment,
previously characterized for their resistance to AZT in vitro
and by nucleotide sequence (12, 13), were also analyzed. Two
uncharacterized viruses from AZT-treated Spanish patients
(1067 and 108) and two from untreated individuals (1910 and
1578) were also included. As with the HIVRTMC-positive
control, the bands diagnostic of mutations at codons 219
and/or 215 (indicated with arrowheads at the right) were
present in viruses 22 and 18 after AZT treatment but were
absent before AZT treatment and in the untreated isolates.
Because Spanish isolates 1067 and 108 also generated the 214-
and 109-nt bands, this result suggested that they were already
mutant, although only at codon 215.
To confirm or rule out this interpretation, we amplified the
genomes from isolates 1067 and 108 by the PCR and se-
quenced the PCR products (data not shown). Isolate 108 had
TAC (tyrosine) at codon 215, while isolate 1067 showed a
mixed population with TAC (tyrosine) and TTC (phenylala-
nine). These are precisely the same mutations previously
described for other AZT-resistant strains (13). As predicted
by the RNase A mismatch experiment, both viruses lacked
the mutation at codon 219.
The results of our analysis of a panel of different HIV
isolates are summarized in Table 1. With the exception of
isolate 2-B, the presence of the 214- and 109-nt bands (see
also Fig. 1) correlated with prolonged AZT therapy, with
resistance to AZT in vitro, and with a mutated codon 215.
Detection of HIV AZT-Resistant Mutants in PBL. To cir-
cumvent the need of virus isolation by cocultivation, we used
a combination of in vitro amplification by the PCR, followed
by mismatch analysis of the amplified DNA-RNA hybrids to
identify directly the mutations in viruses present in the blood
of infected individuals. The results of a mismatch analysis of
PCR-amplified HIV DNA sequences using total cellular RNA
from PBL are shown in Fig. 3. When PCR-amplified DNA
from cultured cells infected with virus HXB2-D (Fig. 3
Lower, lane 1) was subjected to RNase A mismatch analysis,
in addition to the 219-nt band corresponding to the protected
RNA-DNA hybrid, other bands of 166 and 53 nt were
generated. These RNA fragments correspond to substantial
RNase cleavage at the mismatch present at codon 172 (see
Fig. 3 Upper) due to a nucleotide change in the clone of the
IIIB HIV isolate pBH10-R3, used for synthesis of the ribo-
probe. The presence of one or few nucleotide changes in an
individual HIV clone is not surprising because of the quasi-
species nature of RNA viruses (6, 11, 25).
When DNA amplified from HIVRTMC provirus (Fig. 3
Lower, lane 2) was similarly processed, it generated the
expected bands of 180 and 127 nt specific for RNase A
cleavage at the mismatch in codon 215. Viruses 11-B and 5-B
(lanes 3 and 4) also generated the bands diagnostic of the
presence of a mutation at codon 215 of the RT gene, in
agreement with the results of Fig. 1. These results indicate
that the circulating viral population from patients 11.B and
5.B contained the double mutation in codon 215 and dem-
onstrate the feasibility of this approach to detect AZT-
resistance mutations directly from peripheral blood of HIV-
infected individuals.
DISCUSSION
We have shown that the RNase A mismatch cleavage method
can be used for the characterization of genetic heterogeneity
and variability of HIV field isolates. The high resolution
achieved in these experiments by standard sequencing gels
not only increases the sensitivity to detect differences be-
tween closely related viruses but also provides a level of
































FIG. 3. Detection of AZT-resistance mutations in HIV sequences
amplified by the PCR from lymphocytes of infected individuals.
(Upper) Sizes of the expected RNA fragments by RNase A cleavage
of the RNA-DNA hybrids after two consecutive PCR reactions, the
second with nested primers (small arrows). Solid vertical bar with
number 172 on top indicates a mutation present in the clone
pBH1O-R3 used for synthesis of the riboprobe. The PCR products
and sizes of the expected RNase A-protected RNA fragments of the
AZT wild type (WT; AZT sensitive) and AZT mutant (MUT; AZT
resistant) viruses are shown with square boxes highlighting the bands
diagnostic of AZT resistance. (Lower) RNase A mismatch assay of
PCR-amplified DNA using total genomic DNA from cultured cells
infected with clones HXB2-D and HIVRTM (lanes 1 and 2) or total
PBL RNA from cases 11-B and 5-B (lanes 3 and 4). Lanes: M and P.
as in Fig. 1; 0, no RNA added to the PCR.
tween different viral isolates. In these gels, the level of
resolution of a single band after autoradiography is about 2
mm, or 10-2 of the length of the relevant region of the gel.
This value can be considered to be the probability for two
RNA fragments to comigrate by coincidence, which there-
fore is not sufficient for determining an interstrain genetic
relatedness. However, the probabilities of coincidental iden-
tical mobilities for two and three bands will be10-4 and 10-6,
respectively, which provides a reasonable level of confidence
for establishing sequence similarities and phylogenetic rela-
tionships between different viral genomes. The application of
this technique may be particularly relevant for the establish-
ment of infectious identity between viruses (see Fig. 1, isolate
1578) in certain situations, as between family members or
patients and health care providers. The exclusion of identity
on the other hand is not possible because only a few nucleo-
tide changes might disrupt the similarities of the RNase
mismatch patterns (see Fig. 1, isolate 7-B).
We have detected genetic relatedness between. several
viruses circulating in the population of homosexuals in San
Diego that also show similarities to the Californian SF-2
reference strain. The relation of San Diego HIV isolates to
the SF-2 prototype, which was not found in the circulating
Spanish viral population, together with the absence of com-
mon bands between these two groups of viruses, suggest
different origins for the majority of the viruses from these
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geographically distinct areas. At the same time, the presence
of detectable similarities between isolates within these areas
suggests a significant epidemiological clustering of viruses
according to their geographical localization.
Although we have used in our studies viruses grown in
culture, which may result in a distortion of the viral master
sequences (25), we believe that the conclusions regarding the
phylogenetic relationships among different isolates are valid
because they are derived by relative comparative analysis of
their corresponding RNase mismatch patterns. The identical
or very similar mismatch patterns frequently obtained with
viruses isolated simultaneously or after short intervals from
the same patients (Fig. 1 and data not shown) and the
concordance of the results on the AZT-resistance mutations
between cultured viruses and those amplified directly from
PBL by the PCR also support this interpretation.
The use of probes corresponding to different regions of the
viral genome increases the accuracy and specificity in estab-
lishing phylogenetic relationships between viruses and also
allows an easy comparative estimation of their relative vari-
ability and mutation rates. For instance, in viruses sequen-
tially isolated from the same individuals, we have found
striking genetic stabilities in some regions of the genome but
dramatic changes in the mismatch pattern in other regions
(data not shown). These results could be explained by
recombination events between different viruses coexisting in
the same individuals or by differential selective pressures for
fixation of mutations, an example of which is the occurrence
of mutations in the RT gene after continued AZT therapy.
We have taken advantage of the ability of the RNase A
mismatch cleavage method to detect point mutations (14-16)
to identify the temporal appearance of resistance to AZT in
HIV isolates from patients with AIDS or ARC receiving
prolonged therapy. The reported occurrence of a double
nucleotide change at codon 215 in AZT-resistant viruses (13)
was especially helpful because double mismatches are effi-
ciently cleaved by the enzyme. This double mutation is
apparently due to the requirement for restricted amino acid
changes, from the threonine present in the wild-type sequence
(ACC) to a tyrosine (TAC) or to phenylalanine (TTC). By
showing that identical double mutations occurred in epidemi-
ologically and geographically distant viruses, our studies have
confirmed the specific association of the double nucleotide
change at codon 215 with the acquisition of the AZT-resistant
phenotype. Our screening of HIV isolates failed also to detect
circulating viruses with the mutated genotype in the absence
of prolonged AZT therapy (Table 1). Whether this is simply
due to the small or early sample of isolates studied or to a less
viable viral phenotype provided by the AZT mutations re-
mains to be seen. In this context, our method could be useful
also because not only would it detect the presence of the
mutations, but also it could establish the epidemiological
interrelationships of the corresponding viruses.
Detection of the mismatch-specific bands corresponding to
mutations at codon 215 of the viral RT gene by the RNase A
method should have applications to determine the time of
acquisition of the AZT-resistant phenotype. This may prove
to be useful to decide on the choice of further therapy.
Acquired resistance to other antiviral drugs for HIV and
other viruses (10), resulting from the acquisition and subse-
quent selection of mutations leading to single amino acid
substitutions, could be similarly analyzed by the experimen-
tal approach described in this work.
Recently, detection of RT codon 215 mutations has been
reported in AZT-treated HIV isolates by PCR and oligonu-
cleotide hybridization (26).
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